Renalytix

Historical price data

Renalytix is a leader in applying artificial intelligence and machine learning to kidney disease diagnostics, with a mission to enable early-stage prediction and risk stratification. Its core technology platform integrates diverse data inputs—including electronic health records, validated biomarkers, and genetic information—to generate actionable clinical insights. The company's primary commercial focus is its KidneyIntelX test, which has received FDA De Novo marketing authorization for specific patient populations and is navigating the U.S. healthcare reimbursement landscape. Renalytix faces significant challenges, including commercialization execution, securing broad insurance coverage, and a constrained financial position, but its AI-driven approach represents a novel strategy in the chronic kidney disease market.

An artificial intelligence-enabled clinical diagnostics platform that integrates electronic health record data, validated biomarkers, and genetic information to generate bioprognostic risk scores for disease progression, starting with kidney disease.

Total raised: $61M

Renalytix competes against the low-cost standard of care (eGFR/UACR), other biomarker companies, and large diagnostic labs. Its key differentiators are its FDA De Novo authorization for a prognostic test in early diabetic kidney disease and its AI-driven, multi-modal platform. However, competition is intensifying in the digital nephrology space.